Company intelligence / Profile preview

ImmunAbs

Seoul, Seoul Special City, South Koreaimmunabs.com ↗

Ownership: Private
Development stage: Phase 1

Overview

ImmunAbs has successfully completed a Phase 1 clinical trial for its lead program, IM-101, a humanized monoclonal antibody targeting complement C5. The trial demonstrated good tolerability and no severe adverse events or dose-limiting toxicity. Efficacy was confirmed by biomarker analysis in healthy volunteers. The company is preparing to advance IM-101 into Phase 2 trials targeting autoimmune diseases with unmet needs.[3][6]

Therapeutic areas: OphthalmologyHematologyImmunologyNeurology
Modalities: Monoclonal antibodies (mAbs)Polyclonal antibodies (research focus)
Industry: Biotech

Drug pipeline

3 assets

IM-101

2 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on ImmunAbs.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ImmunAbs.

Explore the full profile